Dr. Hesham Amin, MD

• Hematology

• Anatomic & Clinical Pathology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Kasr El Aini College Of Medicine / University Of Cairo

  Medical School, 1982

• Bayesian Edge Regression in Undirected Graphical Models to Characterize Interpatient Heterogeneity in Cancer, 2022-01-05

• TrkA is a binding partner of NPM - ALK that promotes the survival of ALK +T-cell lymphoma, 2017-06-18

• Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma, 2016-09-16

• Zyxin inhibits the epithelial-mesenchymal transition process in gastric cancer by upregulating SIRT1, 2023-09-03

• Enhancing Antigen Retrieval To Unmask Signaling Phosphoproteins In Formalin-Fixed Archival Tissues, 2022-03-22

• Type I insulin-like growth factor receptor signaling in hematological malignancies, 2016-09-19

• DAXX inhibits cancer stemness and epithelial-mesenchymal transition in gastric cancer, 2020-03-23

• Impact of Integrating IGF-1 Levels Into MELD Score for Survival Prediction in Hepatocellular Carcinoma Patients, 2020-10-07

• MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not ade novophenomenon, 2016-07-13

• Loss of p53 and altered miR15-a/16-1?MCL-1 pathway in CLL: insights fromTCL1-Tg:p53-/-mouse model and primary human leukemia cells, 2013-04-23

• Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib, 2021-04-13

• Origin and role of hepatic myofibroblasts in hepatocellular carcinoma, 2020-03-31

• Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab, 2014-11-08

• The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma, 2023-10-07

• Reversal of Bortezomib Resistance in Myelodysplastic Syndrome Cells by MAPK Inhibitors, 2014-03-07

• NPM-ALK upregulates iNOS expression through a STAT3/microRNA-26a- dependent mechanism, 2013-03-14

• Downregulation of HADH promotes gastric cancer progression via Akt signaling pathway, 2017-07-18

• Validation of a preclinical model of diethylnitrosamine-induced hepatic neoplasia in Yucatan miniature pigs, 2016-06-16

• The transcription factors Ik-1 and MZF1 downregulateIGF-IRexpression in NPM-ALK+T-cell lymphoma, 2015-02-25

• SSBP2is anin vivotumor suppressor and regulator of LDB1 stability, 2010-03-29

• Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients, 2022-12-06

• Inhibition of the NADPH oxidase regulates HO-1 expression in chronic myeloid leukemia, 2011-12-02

• IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers, 2020-07-02

• Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA, 2019-07-30

• Requirement forSsbp2in Hematopoietic Stem Cell Maintenance and Stress Response, 2014-09-19

• Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma, 2022-10-06

• CCND1mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma, 2016-10-04

• A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies, 2015-06-23

• Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma, 2018-12-28

• Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma, 2015-05-19

• Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+T-cell lymphoma, 2019-07-24

• Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms, 2015-04-02

• Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+T-cell lymphoma, 2023-06-13